WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced that the U.S. Patent and Trademark Office has issued a new patent covering its lead investigational therapy, istaroxime, for intravenous treatment of acute heart failure (AHF). The patent, application number 18/150,870, is expected to provide protection through 2039.
Istaroxime is an innovative, first-in-class therapy designed to enhance both the pumping (systolic) and relaxing (diastolic) functions of the heart. By employing a dual mechanism of action—stimulating myocardial contractility via Na+/K+-ATPase inhibition and promoting myocardial relaxation through SERCA2a activation—istaroxime aims to improve cardiac performance without raising heart rate or causing significant rhythm disturbances.
The therapy has already shown promise in clinical development, with two positive Phase 2 studies in AHF and two encouraging early studies in cardiogenic shock caused by acute heart failure. Windtree’s leadership views this patent milestone as a critical step forward as istaroxime nears Phase 3 readiness.
“We are pleased to strengthen our intellectual property for istaroxime with this patent for the United States,” said Jed Latkin, CEO of Windtree. “Istaroxime is approaching Phase 3 readiness in cardiogenic shock and acute heart failure. If istaroxime is approved in AHF, this patent would provide protection until 2039. We believe the profile of istaroxime is differentiated from currently available drugs and drug treatment innovation is desired for patients.”
Acute heart failure remains a serious global health burden, affecting millions of patients and driving high rates of hospitalization. Windtree’s progress with istaroxime represents a significant potential advance in addressing the unmet needs in this challenging therapeutic area.
As the company moves closer to late-stage trials, the new patent strengthens its competitive position and reinforces investor confidence in its strategy to bring novel cardiovascular therapies to market.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.